Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Coumarin-induced abnormal factor IX: an immunological study in humans

A Girolami, A Sticchi, A Burul

    Folia Haematologica (Leipzig, Germany : 1928)
    |January 1, 1978
    PubMed
    Summary

    Coumarin treatment in patients results in higher levels of factor IX antigen than activity, indicating a functional deficiency. This abnormal factor IX protein exhibits distinct migration patterns in electrophoresis compared to normal factor IX.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII.

    British journal of haematology·1996
    Same author

    Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation.

    Thrombosis and haemostasis·1996
    Same author

    Type I factor XIII deficiency is caused by a genetic defect of its b subunit: insertion of triplet AAC in exon III leads to premature termination in the second Sushi domain.

    Blood·1996
    Same author

    The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women.

    Thrombosis and haemostasis·1996
    Same author

    "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.

    Thrombosis and haemostasis·1996
    Same author

    Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation.

    British journal of haematology·1996

    Area of Science:

    • Biochemistry
    • Hematology
    • Pharmacology

    Background:

    • Coumarin anticoagulants are widely used but can cause bleeding disorders.
    • Factor IX is a crucial clotting protein, and its deficiency leads to hemophilia B.
    • Understanding the molecular changes in factor IX due to coumarin is essential for managing anticoagulant therapy.

    Purpose of the Study:

    • To investigate the discrepancies between factor IX antigen levels and clotting activity in coumarin-treated patients.
    • To characterize the properties of factor IX protein affected by coumarin administration.
    • To differentiate coumarin-induced factor IX abnormalities from those seen in hemophilia B.

    Main Methods:

    • Quantitative analysis of factor IX antigen and clotting activity in 16 coumarin-treated patients.
    • Electrophoretic techniques, including electroimmunoassay and bidimensional immunoelectrophoresis, were employed.
    • Comparison of migration patterns of factor IX from coumarin-treated patients, normal individuals, and hemophilia B patients.

    Main Results:

    • Coumarin-treated patients showed significantly higher factor IX antigen levels (96.2) compared to clotting activity (19) (p < 0.001).
    • Electrophoresis revealed a distinct, more anodic migration of coumarin-induced abnormal factor IX.
    • Factor IX protein in hemophilia B, BM, and B+ patients migrated normally, unlike the coumarin-affected protein.

    Conclusions:

    • Coumarin treatment induces a dysfunctional form of factor IX, characterized by excess antigen and reduced activity.
    • The altered electrophoretic mobility of coumarin-induced factor IX provides a method for distinguishing it from normal factor IX and hemophilic variants.
    • These findings highlight the importance of assessing both factor IX antigen and activity in patients on coumarin therapy.

    Related Experiment Videos